Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion

Vascular endothelial growth factor (VEGF)/vascular permeability factor is one of the most frequently expressed angiogenic factors in several pathological tissues. Development of VEGF antagonists has become an important approach in the treatment of angiogenesis-dependent diseases. Here we describe a novel anti-VEGF strategy by preventing the secretion of VEGF. We utilize the fact that placenta growth factor (PlGF)-1, a member of the VEGF family lacking detectable angiogenic activity, preferentially forms intracellular heterodimers with VEGF in cells coexpressing both factors. We constructed a retroviral vector containing human PlGF-1 or VEGF with a C-terminal KDEL sequence, which is a mammalian retention signal for the endoplasmic reticulum. Transduction of murine Lewis lung carcinoma cells with the retro-hPlGF-1-KDEL construct almost completely abrogated tumor growth. Consistent with the dramatic antitumor effect, most mouse VEGF molecules remained as intracellular mVEGF/hPlGF-1 heterodimers, and only a negligible amount of mVEGF homodimers were secreted. As a result, in hPlGF-1-KDEL–expressing tumors, blood vessels remained at very low numbers and lacked branching and capillary networks. Gene transfer of a hVEGF-KDEL construct into tumor cells likewise produced a dramatic antitumor effect. Thus, our study provides a novel antiangiogenic approach by preventing the secretion of VEGF.

[1]  Janet S. Dodd,et al.  References , 2003, Dividing Paradise.

[2]  M. Mccarthy.  Antiangiogenesis drug promising for metastatic colorectal cancer , 2003, The Lancet.

[3]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[4]  Li Xiaoying,et al.  A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor* , 2002, The Journal of Biological Chemistry.

[5]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[6]  K. Garber.  Angiogenesis inhibitors suffer new setback , 2002, Nature Biotechnology.

[7]  D. Hicklin,et al.  Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis , 2002, The Journal of experimental medicine.

[8]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[9]  Yihai Cao,et al.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.

[10]  D. Mukhopadhyay,et al.  Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* , 2001, The Journal of Biological Chemistry.

[11]  T. Kuno,et al.  Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. , 2001, The Kobe journal of medical sciences.

[12]  Y. Cao,et al.  Endogenous angiogenesis inhibitors and their therapeutic implications. , 2001, The international journal of biochemistry & cell biology.

[13]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[15]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[16]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[17]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[18]  H. Dvorak,et al.  VPF/VEGF and the angiogenic response. , 2000, Seminars in perinatology.

[19]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[20]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[21]  A. Albini,et al.  c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Yihai Cao,et al.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.

[24]  E. Keshet,et al.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Y. Cao,et al.  Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. , 1997, Biochemical and biophysical research communications.

[26]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[27]  J. Folkman,et al.  In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. , 1996, The Journal of clinical investigation.

[28]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[29]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[30]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[31]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[32]  S. Kondo,et al.  Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. , 1995, Cancer research.

[33]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[34]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[36]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[37]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[38]  G. Viglietto,et al.  Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. , 1993, Oncogene.

[39]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[41]  V. Vincenti,et al.  Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.

[42]  K. Alitalo,et al.  Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. , 1999, Current topics in microbiology and immunology.

[43]  D. Maglione.  Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .